Tag Archives: antibody-drug conjugate

AstraZeneca and Daiichi Sankyo’s Enhertu-based regimen shows 44% risk reduction and over three-year PFS in HER2-positive metastatic breast cancer

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application for Enhertu plus pertuzumab has been accepted for Priority Review by the FDA for the first-line treatment of HER2-positive metastatic breast cancer. The application is supported by data from the … Read the full press release

GSK’s Blenrep Combinations Receive Approval in Japan for Relapsed or Refractory Multiple Myeloma Treatment

(IN BRIEF) GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma. The approval follows positive results from the DREAMM-7 and DREAMM-8 phase III trials, … Read the full press release

FDA Grants Priority Review for AstraZeneca and Daiichi Sankyo’s Datopotamab Deruxtecan for EGFR-Mutated Lung Cancer

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted by the U.S. FDA for treating advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies. The … Read the full press release

Cancer Treatment Advances: FDA Recognizes Breakthrough Potential of BNT323/DB-1303 for Endometrial Cancer

(IN BRIEF) BioNTech and Duality Biologics have received Breakthrough Therapy designation from the FDA for their antibody-drug conjugate (ADC) candidate, BNT323/DB-1303. The designation is for the treatment of advanced endometrial cancer in patients who have progressed following immune checkpoint inhibitor … Read the full press release

Merck and Hengrui Unite for Pioneering Cancer Therapies Worldwide

(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release